Back to top

Image: Bigstock

NextGen's (NXGN) Platform Gets Adopted by FPA Women's Health

Read MoreHide Full Article

NextGen Healthcare, Inc. (NXGN - Free Report) recently announced that FPA Women’s Health deployed its integrated NextGen Patient Experience Platform to offer continuity of care during the COVID-19 pandemic.

Notably, FPA Women’s Health is a mid-sized specialty medical group committed to women’s healthcare.

This is likely to bolster NextGen’s presence in the global healthcare information technology (HCIT) space.

More on the Development

Within the NextGen Patient Experience Platform, FPA Women’s Health leveraged NextGen Virtual Visits to continue treating patients with a wide range of services, such as contraceptive counseling and refills, UTI or STI treatment and the follow-ups on lab results. Moreover, the clinic deployed NextGen Patient Self-Scheduling to make after-hours scheduling convenient and more accessible to staff and patients during the ongoing global health emergency.

Integration with the NextGen Enterprise EHR for patient self-scheduling and virtual visit solutions lessened the risk of duplicative chart problems, which is a major challenge.

Notable Developments

In September 2020, management announced that the company’s next-generation behavioral health suite is available. Backed by a renowned electronic health record (EHR) and practice management system, this health arm is the industry’s only platform that amalgamates physical, behavioral and oral health into an all-inclusive package of a single software solution.

Earlier in August, Virginia Cardiovascular Specialists, the largest private cardiology practice in Central Virginia, implemented NextGen Virtual Visits to extend care and treatment for non-urgent visits utilizing telehealth during the pandemic situation.

Market Prospects

Per a recent Verify Markets report, the virtual healthcare market is expected to reach a worth of more than $3.5 billion by 2022, seeing a CAGR of 49.8% during the forecast period.

Price Performance

Shares of this currently Zacks Rank #4 (Sell) company have gained 14.6% in a year’s time compared with the industry’s growth of 26.8%.

Key Picks

Some better-ranked stocks from the broader medical space are McKesson Corporation (MCK - Free Report) , DaVita Inc (DVA - Free Report) and IDEXX Laboratories (IDXX - Free Report) ,each carrying a Zacks Rank #2 (Buy), presently. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

McKesson has a projected long-term earnings growth rate of 6.6%.

DaVita has an expected long-term earnings growth rate of 18.3%.

IDEXX has an estimated long-term earnings growth rate of 15.8%.

5 Stocks Set to Double

Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth.

Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.

Today, See These 5 Potential Home Runs >>